Current applications of nanoparticles in infectious diseases
For decades infections have been treated easily with drugs. However, in the 21st century,
they may become lethal again owing to the development of antimicrobial resistance …
they may become lethal again owing to the development of antimicrobial resistance …
Current insights on antifungal therapy: Novel nanotechnology approaches for drug delivery systems and new drugs from natural sources
The high incidence of fungal infections has become a worrisome public health issue, having
been aggravated by an increase in host predisposition factors. Despite all the drugs …
been aggravated by an increase in host predisposition factors. Despite all the drugs …
Paracoccidioidomycosis: eco-epidemiology, taxonomy and clinical and therapeutic issues
Acquired by inhalation of the thermal dimorphic fungi Paracoccidioides spp. conidia,
paracoccidioidomycosis ranges from symptomatic to severe and potentially fatal …
paracoccidioidomycosis ranges from symptomatic to severe and potentially fatal …
Early state research on antifungal natural products
Nosocomial infections caused by fungi have increased greatly in recent years, mainly due to
the rising number of immunocompromised patients. However, the available antifungal …
the rising number of immunocompromised patients. However, the available antifungal …
Therapies and vaccines based on nanoparticles for the treatment of systemic fungal infections
B Kischkel, SA Rossi, SR Santos… - Frontiers in cellular …, 2020 - frontiersin.org
Treatment modalities for systemic mycoses are still limited. Currently, the main antifungal
therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of …
therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of …
Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats
Amphotericin B (AMB) is used most commonly in severe systemic life-threatening fungal
infections. There is currently an unmet need for an efficacious (AMB) formulation amenable …
infections. There is currently an unmet need for an efficacious (AMB) formulation amenable …
Antifungal resistance, metabolic routes as drug targets, and new antifungal agents: an overview about endemic dimorphic fungi
JA Parente-Rocha, AM Bailão… - Mediators of …, 2017 - Wiley Online Library
Diseases caused by fungi can occur in healthy people, but immunocompromised patients
are the major risk group for invasive fungal infections. Cases of fungal resistance and the …
are the major risk group for invasive fungal infections. Cases of fungal resistance and the …
Antifungal therapy for systemic mycosis and the nanobiotechnology era: improving efficacy, biodistribution and toxicity
Fungal diseases have been emerging as an important public health problem worldwide with
the increase in host predisposition factors due to immunological dysregulations …
the increase in host predisposition factors due to immunological dysregulations …
Apigenin-loaded PLGA-DMSA nanoparticles: a novel strategy to treat melanoma lung metastasis
R Sen, S Ganguly, S Ganguly, MC Debnath… - Molecular …, 2021 - ACS Publications
The flavone apigenin (APG), alone as well as in combination with other chemotherapeutic
agents, is known to exhibit potential anticancer effects in various tumors and inhibit growth …
agents, is known to exhibit potential anticancer effects in various tumors and inhibit growth …
Comparative genomics allowed the identification of drug targets against human fungal pathogens
AKR Abadio, ES Kioshima, MM Teixeira, NF Martins… - BMC genomics, 2011 - Springer
Background The prevalence of invasive fungal infections (IFIs) has increased steadily
worldwide in the last few decades. Particularly, there has been a global rise in the number of …
worldwide in the last few decades. Particularly, there has been a global rise in the number of …